Biomarker-Guided TGF-β2 Antisense Combination Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional cancer therapies lack efficacy across various cancers and are associated with significant side effects and toxicity, necessitating the development of synergistic therapies that enhance anti-tumor effects while minimizing adverse health impacts.
Innovation Solution
Combining agents that inhibit TGF-β2 expression with checkpoint inhibitors and interleukin immunotherapeutics, guided by biomarkers like IRF5 and ITGAM, to treat a range of cancers, including pancreatic cancer, melanoma, and others, using formulations that can be administered concurrently, simultaneously, or sequentially.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer therapies are used, then cancer cells are killed, but healthy cells are also damaged and toxicity increases
Solution Approach 1:
The therapy is segmented into multiple targeted components: TGF-β2 inhibition specifically targets tumor microenvironment suppression, checkpoint inhibitors specifically target immune checkpoint pathways, and interleukin agents specifically target immune activation. This segmentation allows each component to act on specific cancer-related pathways while sparing healthy tissues from broad cytotoxic effects.
Solution Approach 2:
The patent uses biomarkers (IRF5, ITGAM) as intermediaries to identify patients who will respond to therapy. These biomarkers serve as mediators between the therapeutic agents and the tumor, enabling selective treatment of patients whose tumors express these markers, thereby reducing unnecessary toxicity in patients who would not benefit.
2Reliability
If conventional cancer therapies are used, then some cancers are treated, but efficacy is insufficient across various cancer types
Solution Approach 1:
The patent combines multiple therapeutic mechanisms into a single regimen that can address diverse cancer types: TGF-β2 inhibition works across solid tumors by reversing immunosuppression, checkpoint inhibitors activate T-cell responses in multiple cancer indications, and interleukin agents provide broad immune stimulation. This multi-functional approach enables the therapy to be effective across pancreatic cancer, melanoma, and other solid tumors.
Solution Approach 2:
The patent changes the therapeutic parameters by using combination therapy with multiple mechanisms of action rather than single-agent therapy. By combining TGF-β2 inhibition, checkpoint blockade, and interleukin stimulation, the therapy achieves enhanced and sustained anti-tumor responses across different cancer types, overcoming the limitations of conventional monotherapies.
3Reliability
If combination therapy with multiple agents is used, then anti-tumor efficacy increases, but treatment complexity increases
Solution Approach 1:
The patent merges three distinct therapeutic mechanisms into a coordinated combination regimen: TGF-β2 inhibition, checkpoint blockade, and interleukin stimulation. By merging these mechanisms that work through different pathways (direct tumor suppression, immune checkpoint release, and immune activation), the therapy achieves synergistic anti-tumor efficacy while managing complexity through rational drug selection.
Data Source
AI summary
This invention relates to agents, uses and methods for cancer designed to promote anti-tumor effects over a range of different cancers. Exemplary synergistic therapies include compositions of combinations of active agents including antisense agents for inhibiting or suppressing expression of TGF-β2, checkpoint inhibitor agents, and interleukin immunotherapeutic agents. One or more biomarkers can be used to select subjects who benefit from the agents, uses and methods, including IRF5 and ITGAM. The agents can be used with chemotherapy and other standard-of-care therapies.